---
title: "DXM - Complete Profile"
substance: "DXM"
chemical_name: "Dextromethorphan"
category: "Dissociative"
legal_status: "OTC Legal (most countries)"
description: "The accessible dissociative - legal cough suppressant that becomes a powerful psychedelic at higher doses"
permalink: "/dyos-domain/substances/dxm/"
---

<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/dissociatives/">Dissociatives</a> ‚Üí <span>DXM</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üåÄ DXM</h1>
        <h2 class="chemical-name">Dextromethorphan</h2>
         <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="DXM" 
                data-category="Dissociatives" 
                data-chemical="Dextromethorphan">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Chemical Names</h4>
              <span>Dextromethorphan</span> ‚Ä¢ <span>DXM</span> ‚Ä¢ <span>3-Methoxy-17-methylmorphinan</span> ‚Ä¢ <span>DXM HBr</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Robo</span> ‚Ä¢ <span>Triple C</span> ‚Ä¢ <span>Dex</span> ‚Ä¢ <span>Skittles</span> ‚Ä¢ <span>Poor Man's PCP</span>
            </div>
            <div class="name-category">
              <h4>Brand Names</h4>
              <span>Robitussin</span> ‚Ä¢ <span>Delsym</span> ‚Ä¢ <span>Mucinex DM</span> ‚Ä¢ <span>Coricidin</span> ‚Ä¢ <span>Vicks</span>
            </div>
            <div class="name-category">
              <h4>Chemical Identifiers</h4>
              <span>CAS: 125-71-3</span> ‚Ä¢ <span>Formula: C‚ÇÅ‚ÇàH‚ÇÇ‚ÇÖNO</span> ‚Ä¢ <span>MW: 271.40 g/mol</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category dissociative">Dissociative</span>
          <span class="legal-status legal">OTC Legal</span>
          <span class="duration long">4-8 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/dxm.jpg" alt="DXM cough syrup bottles, gel caps and molecular structure" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇÅ‚ÇàH‚ÇÇ‚ÇÖNO</p>
            <p>MW: 271.40 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pure DXM (HBr salt)</h4>
          <ul>
            <li><strong>Appearance:</strong> White crystalline powder</li>
            <li><strong>Texture:</strong> Fine crystalline powder, slightly hygroscopic</li>
            <li><strong>Odor:</strong> Faint, slightly medicinal smell</li>
            <li><strong>Taste:</strong> Extremely bitter and numbing</li>
            <li><strong>Solubility:</strong> Freely soluble in water and alcohol</li>
            <li><strong>Stability:</strong> Stable under normal conditions</li>
          </ul>
        </div>
        
        <div class="commercial-forms">
          <h4>Commercial OTC Forms</h4>
          <ul>
            <li><strong>Cough syrups:</strong> Liquid form, often cherry/grape flavored (15-30mg/5mL)</li>
            <li><strong>Gel capsules:</strong> Soft gels, typically 15mg each (most common for abuse)</li>
            <li><strong>Tablets:</strong> Hard tablets, various strengths (15-30mg)</li>
            <li><strong>Extended-release:</strong> Delsym and similar (polistirex formulation)</li>
            <li><strong>Powder form:</strong> Pure DXM powder (research/bulk sources)</li>
          </ul>
        </div>
        
        <div class="dangerous-combinations">
          <h4>‚ö†Ô∏è Dangerous Combination Products</h4>
          <p><strong>Triple C (Coricidin):</strong> Contains chlorpheniramine - dangerous at DXM abuse doses</p>
          <p><strong>Multi-symptom formulas:</strong> Contain acetaminophen, guaifenesin, phenylephrine</p>
          <p><strong>DXM + Acetaminophen:</strong> Liver damage risk at high doses</p>
          <p><strong>Safe products:</strong> DXM-only formulations (Robitussin DM, pure gel caps)</p>
        </div>
        
        <div class="formulation-differences">
          <h4>üß™ HBr vs. Polistirex</h4>
          <p><strong>DXM HBr:</strong> Immediate release, shorter duration (4-8 hours), more intense</p>
          <p><strong>DXM Polistirex:</strong> Extended release, longer duration (8-12 hours), less intense peak</p>
          <p><strong>Potency difference:</strong> Polistirex ~50% potency of HBr by weight</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines - Plateau System</h3>
      
      <div class="plateau-system">
        <h4>üèîÔ∏è The Four Plateau System</h4>
        <div class="dosage-chart">
          <div class="dose-range first-plateau">
            <span class="range-label">1st Plateau</span>
            <span class="dose-amount">1.5-2.5mg/kg</span>
            <div class="dose-bar"></div>
            <span class="effects-preview">Mild euphoria, music enhancement</span>
          </div>
          <div class="dose-range second-plateau">
            <span class="range-label">2nd Plateau</span>
            <span class="dose-amount">2.5-7.5mg/kg</span>
            <div class="dose-bar"></div>
            <span class="effects-preview">Drunk-like dissociation, closed-eye visuals</span>
          </div>
          <div class="dose-range third-plateau">
            <span class="range-label">3rd Plateau</span>
            <span class="dose-amount">7.5-15mg/kg</span>
            <div class="dose-bar"></div>
            <span class="effects-preview">Strong dissociation, out-of-body experiences</span>
          </div>
          <div class="dose-range fourth-plateau">
            <span class="range-label">4th Plateau</span>
            <span class="dose-amount">15mg/kg+</span>
            <div class="dose-bar"></div>
            <span class="effects-preview">Complete dissociation, hole-like experiences</span>
          </div>
        </div>
      </div>
      
      <div class="plateau-descriptions">
        <h4>Detailed Plateau Effects</h4>
        <div class="plateau-detail">
          <h5>1st Plateau (100-200mg for 70kg person)</h5>
          <p>Mild stimulation, music enhancement, slight euphoria. Similar to mild alcohol intoxication but with enhanced sensory perception.</p>
        </div>
        <div class="plateau-detail">
          <h5>2nd Plateau (200-400mg for 70kg person)</h5>
          <p>Moderate dissociation, impaired motor coordination, closed-eye visuals, drunk-like state with psychedelic elements.</p>
        </div>
        <div class="plateau-detail">
          <h5>3rd Plateau (400-800mg for 70kg person)</h5>
          <p>Strong dissociation, out-of-body experiences, significant impairment, dream-like states, potential for dangerous behavior.</p>
        </div>
        <div class="plateau-detail">
          <h5>4th Plateau (800mg+ for 70kg person)</h5>
          <p>Complete ego dissolution, hole-like experiences, extreme danger of injury, blackouts, potential psychological trauma.</p>
        </div>
      </div>
      
      <div class="metabolism-factors">
        <h4>üß¨ CYP2D6 Metabolism Warning</h4>
        <ul>
          <li><strong>Extensive metabolizers:</strong> Normal DXM ‚Üí DXO conversion (most people)</li>
          <li><strong>Poor metabolizers (8-10%):</strong> Reduced DXO production, different effects</li>
          <li><strong>Ultra-rapid metabolizers:</strong> Faster conversion, shorter duration</li>
          <li><strong>First-time warning:</strong> Start low due to unknown metabolizer status</li>
          <li><strong>SSRI interaction:</strong> CYP2D6 inhibition changes metabolism significantly</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Critical Warning:</strong> DXM dosing is weight-dependent and affected by individual metabolism. Poor metabolizers can experience dangerous effects at normal doses.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline - HBr Formulation</h4>
        <div class="timeline-item">
          <span class="time">T+0:30-1:30</span>
          <span class="effect">Onset - nausea, body load, initial dissociation</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+1:30-4:00</span>
          <span class="effect">Peak - plateau effects, maximum dissociation</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+4:00-8:00</span>
          <span class="effect">Plateau - sustained effects at plateau level</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+8:00-12:00</span>
          <span class="effect">Comedown - gradual return, residual dissociation</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+12:00-24:00</span>
          <span class="effect">After-effects - hangover, grogginess, depression</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÖ Positive Effects</h4>
          <ul>
            <li>Music enhancement and euphoria (1st plateau)</li>
            <li>Dissociative anesthesia and pain relief</li>
            <li>Closed and open-eye visual distortions</li>
            <li>Out-of-body and floating sensations</li>
            <li>Altered perception of time and space</li>
            <li>Dream-like states and introspection</li>
            <li>Reduced anxiety and emotional numbness</li>
            <li>Novel thought patterns and insights</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùå Challenging Effects</h4>
          <ul>
            <li>Severe nausea and vomiting (especially onset)</li>
            <li>Motor impairment and loss of coordination</li>
            <li>Confusion and disorientation</li>
            <li>Memory impairment and blackouts</li>
            <li>Respiratory depression at high doses</li>
            <li>Hyperthermia and excessive sweating</li>
            <li>Post-trip depression and cognitive fog</li>
            <li>Potential for dangerous behavior while dissociated</li>
          </ul>
        </div>
      </div>

      <div class="unique-characteristics">
        <h4>üåÄ DXM's Unique Profile</h4>
        <ul>
          <li><strong>Sigma receptor activity:</strong> Unique among dissociatives, contributes to psychotic-like effects</li>
          <li><strong>Serotonin reuptake inhibition:</strong> Antidepressant-like activity, dangerous with SSRIs</li>
          <li><strong>Plateau system:</strong> Distinct dose-dependent experience levels</li>
          <li><strong>Music enhancement:</strong> Particularly strong music appreciation effects</li>
          <li><strong>Body load:</strong> Significant physical discomfort, especially nausea</li>
          <li><strong>Cognitive impairment:</strong> More impairing than other dissociatives</li>
        </ul>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>DXM is primarily an NMDA receptor antagonist, but unlike other dissociatives, it has significant activity at multiple other targets. It's a serotonin reuptake inhibitor (SRI), sigma-1 receptor agonist, and has activity at Œ±3Œ≤4 nicotinic receptors. Its active metabolite dextrorphan (DXO) is a more potent NMDA antagonist, while DXM itself contributes more serotonergic effects.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>NMDA receptor</strong></span>
            <span class="affinity">Moderate antagonist (DXM), High antagonist (DXO)</span>
            <span class="function">Primary dissociative effects, anesthesia, out-of-body experiences</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>SERT (Serotonin transporter)</strong></span>
            <span class="affinity">Moderate inhibition (Ki: 1.1 ŒºM)</span>
            <span class="function">Antidepressant effects, dangerous interactions with SSRIs</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Sigma-1 receptor</strong></span>
            <span class="affinity">High affinity agonist (Ki: 0.1 ŒºM)</span>
            <span class="function">Psychotomimetic effects, unique among dissociatives</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ±3Œ≤4 nicotinic receptor</strong></span>
            <span class="affinity">Moderate antagonist</span>
            <span class="function">May contribute to some cognitive effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>NET (Norepinephrine transporter)</strong></span>
            <span class="affinity">Weak inhibition</span>
            <span class="function">Minor stimulant effects</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary metabolism:</strong> CYP2D6 O-demethylation ‚Üí Dextrorphan (DXO)</p>
          <p><strong>Secondary metabolism:</strong> CYP3A4 N-demethylation ‚Üí 3-methoxymorphinan</p>
          <p><strong>Active metabolite:</strong> DXO is more potent NMDA antagonist than DXM</p>
          <p><strong>Half-life:</strong> DXM: 3-4 hours, DXO: 6-8 hours</p>
          <p><strong>CYP2D6 polymorphism:</strong> Poor metabolizers have different experience profile</p>
          <p><strong>Peak plasma:</strong> 2-3 hours for HBr, longer for polistirex</p>
        </div>

        <h4>Unique Pharmacological Features</h4>
        <ul>
          <li><strong>Dual compound system:</strong> DXM + DXO create combined effects</li>
          <li><strong>Sigma receptor activity:</strong> Unique among recreational dissociatives</li>
          <li><strong>Serotonin reuptake inhibition:</strong> Creates antidepressant and interaction risks</li>
          <li><strong>CYP2D6 dependence:</strong> Individual metabolism hugely affects experience</li>
          <li><strong>Multiple receptor targets:</strong> More complex pharmacology than ketamine/PCP</li>
          <li><strong>Plateau phenomenon:</strong> Distinct dose-response relationship</li>
        </ul>

        <h4>Tolerance & Dependence</h4>
        <div class="tolerance-info">
          <p><strong>Tolerance development:</strong> Rapid tolerance to dissociative effects</p>
          <p><strong>Cross-tolerance:</strong> Partial cross-tolerance with other NMDA antagonists</p>
          <p><strong>Physical dependence:</strong> Can develop with regular use</p>
          <p><strong>Withdrawal syndrome:</strong> Depression, fatigue, cognitive impairment</p>
          <p><strong>Psychological dependence:</strong> High potential due to accessibility</p>
        </div>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Safety Warnings</h4>
          <ul>
            <li><strong>Serotonin syndrome:</strong> Dangerous with SSRIs, MAOIs, other serotonergic drugs</li>
            <li><strong>Respiratory depression:</strong> Risk at high doses, especially with other depressants</li>
            <li><strong>Hyperthermia:</strong> Dangerous overheating, especially in hot environments</li>
            <li><strong>Combination products:</strong> Many OTC formulas contain dangerous additives</li>
            <li><strong>Motor impairment:</strong> Extreme coordination loss, fall/injury risk</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°Ô∏è Essential Precautions</h4>
          <ul>
            <li><strong>DXM-only products:</strong> Avoid multi-ingredient formulations</li>
            <li><strong>Safe environment:</strong> Padded area, remove hazards, sitter present</li>
            <li><strong>Start low:</strong> Unknown CYP2D6 status makes first experiences unpredictable</li>
            <li><strong>Empty stomach:</strong> Reduces nausea but increases absorption speed</li>
            <li><strong>Temperature control:</strong> Cool environment, monitor for overheating</li>
            <li><strong>No driving:</strong> Impairment lasts many hours beyond subjective effects</li>
          </ul>
        </div>
      </div>

      <div class="product-safety">
        <h4>üíä Safe Product Selection</h4>
        <ul>
          <li><strong>Safe products:</strong> Robitussin DM (liquid), pure DXM gel caps, Delsym</li>
          <li><strong>Dangerous products:</strong> Coricidin (Triple C), Tylenol PM formulas</li>
          <li><strong>Read labels:</strong> Ensure DXM is the ONLY active ingredient</li>
          <li><strong>Avoid generics:</strong> Some contain unlisted active ingredients</li>
          <li><strong>Calculate doses:</strong> Know exact DXM content per dose unit</li>
        </ul>
      </div>

      <div class="contraindications">
        <h4>üö´ Absolute Contraindications</h4>
        <p><strong>Do not use if you have:</strong> Taking SSRIs, MAOIs, or other psychiatric medications; respiratory conditions; liver disease; heart conditions; seizure disorders; or are a poor CYP2D6 metabolizer. The combination with serotonergic medications can be fatal.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Extremely Dangerous</h4>
          <ul>
            <li><strong>SSRIs/SNRIs:</strong> Serotonin syndrome, potentially fatal hyperthermia</li>
            <li><strong>MAOIs:</strong> Severe serotonin syndrome, hypertensive crisis</li>
            <li><strong>Tramadol:</strong> Seizure risk, serotonin syndrome</li>
            <li><strong>St. John's Wort:</strong> Serotonin syndrome risk</li>
            <li><strong>5-HTP/Tryptophan:</strong> Excessive serotonin activity</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° High Risk</h4>
          <ul>
            <li><strong>Alcohol:</strong> Respiratory depression, increased impairment</li>
            <li><strong>Benzodiazepines:</strong> Respiratory depression risk</li>
            <li><strong>Opioids:</strong> Respiratory depression, potentially fatal</li>
            <li><strong>Other dissociatives:</strong> Unpredictable potentiation</li>
            <li><strong>Stimulants:</strong> Hyperthermia risk, cardiovascular strain</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Use Extreme Caution</h4>
          <ul>
            <li><strong>CYP2D6 inhibitors:</strong> Quinidine, bupropion alter metabolism</li>
            <li><strong>Antihistamines:</strong> Increased sedation and confusion</li>
            <li><strong>Cannabis:</strong> May increase dissociation and confusion</li>
            <li><strong>Grapefruit juice:</strong> CYP3A4 inhibition may affect metabolism</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>üá∫üá∏ United States</h4>
            <p><strong>OTC Legal</strong> - Available without prescription in cough medications. Some states restrict sales to minors or bulk purchases.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¨üáß United Kingdom</h4>
            <p><strong>OTC Legal</strong> - Available in pharmacy medicines, some restrictions on quantities.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá®üá¶ Canada</h4>
            <p><strong>OTC Legal</strong> - Available without prescription, some provincial restrictions.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¶üá∫ Australia</h4>
            <p><strong>Schedule 2</strong> - Pharmacy medicine, available without prescription.</p>
          </div>
        </div>
        
        <div class="regulatory-trends">
          <h4>üìä Regulatory Trends</h4>
          <p>Increasing awareness of DXM abuse has led to some retailers implementing age restrictions, quantity limits, and ID requirements. Some jurisdictions are considering tighter controls on bulk DXM products while maintaining medical availability.</p>
        </div>
        
        <div class="legal-concerns">
          <h4>‚öñÔ∏è Legal Considerations</h4>
          <p>While DXM itself is legal, purchasing large quantities or extracting pure DXM may raise suspicions. Some states have specific laws about abuse of OTC medications, and driving under the influence of DXM carries the same penalties as alcohol DUI.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1954</span>
          <p>DXM first synthesized as safer alternative to codeine</p>
        </div>
        <div class="history-event">
          <span class="year">1958</span>
          <p>FDA approves DXM for OTC cough suppression</p>
        </div>
        <div class="history-event">
          <span class="year">1960s</span>
          <p>First reports of recreational DXM use and abuse</p>
        </div>
        <div class="history-event">
          <span class="year">1970s-80s</span>
          <p>Underground awareness grows, "robotripping" terminology emerges</p>
        </div>
        <div class="history-event">
          <span class="year">1990s</span>
          <p>Internet forums spread information about DXM plateau system</p>
        </div>
        <div class="history-event">
          <span class="year">2000s</span>
          <p>Rising teen abuse rates, media attention, some regulatory responses</p>
        </div>
        <div class="history-event">
          <span class="year">2010s</span>
          <p>Research into therapeutic potential for depression, stroke recovery</p>
        </div>
      </div>

      <div class="underground-culture">
        <h4>üåê Internet Culture & Robotripping</h4>
        <p>DXM gained a unique place in internet drug culture due to its legal availability and distinctive effects. Online communities developed detailed guides for safe use, plateau calculators, and extensive trip reports. The term "robotripping" (from Robitussin) became synonymous with DXM use, and the substance developed a reputation as an accessible but potentially dangerous dissociative.</p>
      </div>

      <div class="abuse-patterns">
        <h4>üìä Abuse Patterns & Demographics</h4>
        <p>DXM abuse is particularly prevalent among teenagers due to its legal availability and presence in many households. Studies show episodic use patterns, with users often escalating to higher plateaus over time. The accessibility creates both opportunity and risk, as users may be unaware of the dangers or proper precautions.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Depression Treatment</h4>
          <p>Research into DXM's antidepressant properties, particularly its serotonin reuptake inhibition combined with NMDA antagonism. Some studies suggest rapid-acting antidepressant effects similar to ketamine.</p>
        </div>
        
        <div class="research-item">
          <h4>Stroke Recovery</h4>
          <p>Investigation of DXM's neuroprotective properties and potential for enhancing recovery from stroke through NMDA receptor modulation and neuroplasticity enhancement.</p>
        </div>
        
        <div class="research-item">
          <h4>Sigma Receptor Function</h4>
          <p>Studies on DXM's unique sigma-1 receptor activity and its contribution to both therapeutic effects and abuse potential, distinguishing it from other dissociatives.</p>
        </div>
        
        <div class="research-item">
          <h4>Addiction Medicine</h4>
          <p>Research into DXM's abuse potential, withdrawal symptoms, and treatment approaches for DXM dependence, particularly in adolescent populations.</p>
        </div>
        
        <div class="research-item">
          <h4>CYP2D6 Pharmacogenetics</h4>
          <p>Studies on how genetic variations in CYP2D6 metabolism affect DXM's safety and efficacy profiles, with implications for personalized medicine approaches.</p>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Resources & Safety Information</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Educational Resources</h4>
        <ul>
          <li><strong>Erowid DXM FAQ:</strong> Comprehensive guide to DXM effects and safety</li>
          <li><strong>DXM Calculator:</strong> Online tools for plateau calculation</li>
          <li><strong>PsychonautWiki:</strong> Detailed pharmacology and harm reduction</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Safety & Support</h4>
        <ul>
          <li><strong>TripSit:</strong> Chat support for difficult experiences</li>
          <li><strong>Poison Control:</strong> Emergency medical guidance</li>
          <li><strong>Fireside Project:</strong> Psychedelic peer support</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Medical Information</h4>
        <ul>
          <li><strong>Drug interaction checkers:</strong> Professional medical databases</li>
          <li><strong>CYP2D6 testing:</strong> Genetic testing for metabolism status</li>
          <li><strong>Emergency protocols:</strong> Serotonin syndrome recognition</li>
        </ul>
      </div>
    </div>
  </div>

  <div class="dxm-special-warning">
    <h3>üö® Critical Safety Reminder</h3>
    <div class="warning-content">
      <p><strong>DXM is deceptively dangerous:</strong> Its legal availability as a cough medicine masks significant risks including serotonin syndrome, respiratory depression, and severe impairment lasting many hours.</p>
      
      <p><strong>Essential safety requirements:</strong></p>
      <ul>
        <li>Use only DXM-only products (no acetaminophen, guaifenesin, etc.)</li>
        <li>Never combine with SSRIs, MAOIs, or other serotonergic drugs</li>
        <li>Start with first plateau doses to assess individual sensitivity</li>
        <li>Have an experienced, sober sitter present for higher plateaus</li>
        <li>Ensure safe environment free of hazards</li>
        <li>Monitor for hyperthermia and respiratory depression</li>
        <li>Wait at least one week between uses to prevent tolerance</li>
      </ul>
      
      <p><strong>When to seek emergency medical care:</strong> High fever, difficulty breathing, severe confusion, loss of consciousness, or any signs of serotonin syndrome (muscle rigidity, rapid heartbeat, excessive sweating).</p>
    </div>
  </div>

</div>